Convertible debt investors are hungry for paper and biotechs are eager to capitalize on this - even those without marketed products and substantial revenues. Over the last decade, biotechs with sizable and growing revenues have primarily...

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...